Berwyn, Pa., Dec. 13, 2019 – EDW Pharma, a U.S.-based specialty pharmaceutical company and subsidiary of Italfarmaco, a privately-held European specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved its application to broaden the existing label for TIGLUTIK® (riluzole) oral suspension to include administration via percutaneous endoscopic gastrostomy (PEG) tubes for the treatment of amyotrophic lateral sclerosis (ALS).

EDW Pharma, a U.S.-based specialty pharmaceutical company committed to investing in and commercializing impactful medicines in therapeutic areas with unfulfilled needs, has united with The ALS Association to fight to defeat ALS.

BERWYN, Pa., Feb. 28, 2019 /PRNewswire/ — EDW Pharma, a U.S.-based specialty pharmaceutical company and a subsidiary of Italfarmaco, a privately-held European specialty pharmaceutical company, committed to investing in and commercializing impactful medicines in therapeutic areas with unfulfilled needs, announced today that the Company has been selected for the 2018 Patient Impact Award by Life Sciences Pennsylvania (LSPA).

BERWYN, Pa., Oct. 15, 2018 /PRNewswire/ — EDW Pharma, a U.S.-based specialty pharmaceutical company and a subsidiary of Italfarmaco, a privately-held European specialty pharmaceutical company, announced today the U.S. availability of its first commercial product, TIGLUTIK™ (riluzole) oral suspension, for the treatment of amyotrophic lateral sclerosis (ALS).  ALS, also commonly known as Lou Gehrig’s disease, is … Read more

Berwyn, Pa., Sept. 6, 2018–EDW Pharma, a U.S.-based specialty pharmaceutical company and a subsidiary of Italfarmaco, a privately-held European specialty pharmaceutical company, committed to investing in and commercializing impactful medicines in therapeutic areas with unfulfilled needs, announced today that the U.S. Food and Drug Administration (FDA) has approved TIGLUTIK™ (riluzole) oral suspension for the treatment … Read more